Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DelNS1-2019-nCoV-RBD-OPT1 Phase II Intranasal COVID-19 Vaccine Trial
ChiCTR2000039715Phase 2Recruiting
- Sponsor
- Jiangsu Provincial Center for Disease Control and Prevention
- Start
- Nov 2020
- Modality
- Vaccines & Immunotherapeutics, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Pneucolin in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Jiangsu Provincial Center for Disease Control and Prevention. Primary endpoints: Serum SARS-CoV-2 total antibody seroconversion and antibody levels, Mucosal SARS-CoV-2 antibody response in nasopharyngeal swabs and 1 more. Started Nov 2020; status: recruiting.
02
Drugs
Pneucolin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2000039715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000039715.